Richard K Turner, MD
Emergency Medicine · San Mateo
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
Offices
3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Turner’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence G50980 · Current
Licensed to practise in California · since 1983 · expires 2027-07-31 · University of California, Los Angeles School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$25,467
Medicare paid this office $25,467 for 185 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 121 | $12,189 | $98 |
| Long return visit (40+ min) | 48 | $7,197 | $144 |
| Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus | 18 | $2,516 | $140 |
| Short return visit (20+ min) | 20 | $1,338 | $67 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 17 | $855 | $50 |
See all 8 services
| Return visit (30+ min) | 121 | $12,189 | $98 |
| Long return visit (40+ min) | 48 | $7,197 | $144 |
| Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus | 18 | $2,516 | $140 |
| Short return visit (20+ min) | 20 | $1,338 | $67 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 17 | $855 | $50 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 25 | $405 | $16 |
| Automated urinalysis test | 31 | $73 | $2 |
| Blood count, hemoglobin | 17 | $39 | $2 |
Who their Medicare patients are
185 Original Medicare patients in 2024. Average age 77 · Women 59% · Health risk score 0.95. At or below the middle of the specialty; the typical emergency medicine clinician is at 2.01.
Conditions among them: High blood pressure 59% · Coronary heart disease 22% · Diabetes 17% · Atrial fibrillation 17% · Cancer 16% · Depression 16% · Heart failure 14% · Chronic kidney disease 14% · COPD 9%.
The office billed $88,598, Medicare allowed $37,015 and paid $25,467; for 361 services of 24 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 185 | 361 | 77 | 0.95 | $88,598 | $25,467 |
| 2023 | 263 | 487 | 76 | 0.98 | $114,924 | $34,514 |
| 2022 | 260 | 526 | 75 | 0.98 | $110,741 | $38,563 |
| 2021 | 279 | 475 | 74 | 1.01 | $113,444 | $39,456 |
| 2020 | 186 | 325 | 72 | 0.97 | $69,571 | $18,760 |
| 2019 | 374 | 748 | 77 | 1.12 | $152,119 | $41,905 |
| 2018 | 326 | 676 | 77 | 1.22 | $130,529 | $36,391 |
| 2017 | 307 | 547 | 76 | 1.08 | $115,796 | $35,874 |
| 2016 | 127 | 211 | 75 | 1.05 | $49,239 | $17,940 |
| 2015 | 209 | 344 | 72 | 1.53 | $94,455 | $23,026 |
| 2014 | 591 | 1,260 | 69 | 2.22 | $375,098 | $87,105 |
| 2013 | 645 | 1,281 | 71 | 2.15 | $410,559 | $98,035 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Return visit (30+ min) | 169 | $18,095 | $104 |
| Long return visit (40+ min) | 62 | $9,888 | $157 |
| Short return visit (20+ min) | 28 | $1,914 | $66 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 21 | $1,056 | $50 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 23 | $373 | $16 |
| Inhalation treatment for airway obstruction or sputum production | 16 | $128 | $8 |
| Insertion of needle into vein for collection of blood sample | 14 | $118 | $8 |
| Automated urinalysis test | 36 | $84 | $2 |
| Blood count, hemoglobin | 26 | $59 | $2 |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 17 | $1 | None |
2022: 10 services
| Return visit (30+ min) | 169 | $19,761 | $113 |
| Long return visit (40+ min) | 38 | $6,534 | $172 |
| New patient visit (45+ min) | 24 | $3,396 | $142 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 45 | $2,272 | $50 |
| Short return visit (20+ min) | 20 | $1,567 | $78 |
| Detection test by nucleic acid for multiple types influenza virus | 11 | $1,034 | $94 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 18 | $293 | $16 |
| Automated urinalysis test | 43 | $95 | $2 |
| Insertion of needle into vein for collection of blood sample | 12 | $35 | $3 |
| Blood count, hemoglobin | 13 | $33 | $2 |
2021: 9 services
| Return visit (30+ min) | 139 | $17,050 | $119 |
| New patient visit (45+ min) | 63 | $8,785 | $139 |
| Long return visit (40+ min) | 26 | $4,017 | $154 |
| Short return visit (20+ min) | 24 | $1,841 | $77 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 33 | $1,745 | $51 |
| New patient visit (30+ min) | 13 | $1,066 | $82 |
| Automated urinalysis test | 35 | $79 | $2 |
| Insertion of needle into vein for collection of blood sample | 14 | $42 | $3 |
| Blood count, hemoglobin | 13 | $31 | $2 |
2020: 6 services
| Long return visit (40+ min) | 67 | $7,666 | $114 |
| Return visit (30+ min) | 61 | $4,098 | $67 |
| New patient visit (45+ min) | 19 | $2,491 | $131 |
| Short return visit (20+ min) | 31 | $1,724 | $56 |
| Automated urinalysis test | 28 | $62 | $2 |
| Blood count, hemoglobin | 17 | $40 | $2 |
2019: 13 services
| Long return visit (40+ min) | 152 | $17,879 | $116 |
| Return visit (30+ min) | 147 | $13,578 | $90 |
| Short return visit (20+ min) | 60 | $3,777 | $62 |
| New patient visit (45+ min) | 13 | $1,599 | $123 |
| Blood test, basic group of blood chemicals (calcium, ionized) | 36 | $485 | $13 |
| Inhalation treatment for airway obstruction or sputum production | 16 | $314 | $18 |
| Detection test by immunoassay with direct visual observation for influenza virus | 15 | $276 | $16 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 17 | $275 | $16 |
| Blood count, hemoglobin | 47 | $124 | $3 |
| Automated urinalysis test | 41 | $105 | $2 |
| Insertion of needle into vein for collection of blood sample | 33 | $97 | $3 |
| Blood glucose (sugar) test performed by hand-held instrument | 16 | $51 | $3 |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 15 | $2 | None |
2018: 13 services
| Long return visit (40+ min) | 106 | $12,768 | $118 |
| Return visit (30+ min) | 144 | $12,160 | $83 |
| New patient visit (45+ min) | 25 | $2,980 | $119 |
| Short return visit (20+ min) | 38 | $2,230 | $59 |
| New patient visit (30+ min) | 12 | $853 | $71 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 29 | $470 | $16 |
| Blood test, basic group of blood chemicals (calcium, ionized) | 32 | $431 | $13 |
| Inhalation treatment for airway obstruction or sputum production | 16 | $343 | $19 |
| Blood count, hemoglobin | 49 | $141 | $3 |
| Insertion of needle into vein for collection of blood sample | 23 | $68 | $3 |
| Automated urinalysis test | 23 | $62 | $3 |
| Blood glucose (sugar) test performed by hand-held instrument | 13 | $42 | $3 |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 17 | $2 | None |
2017: 11 services
| Long return visit (40+ min) | 91 | $10,588 | $114 |
| Return visit (30+ min) | 106 | $9,979 | $92 |
| New patient visit (45+ min) | 60 | $7,454 | $124 |
| Short return visit (20+ min) | 31 | $1,990 | $62 |
| New patient visit (30+ min) | 13 | $1,076 | $83 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 17 | $212 | $12 |
| Blood test, basic group of blood chemicals (calcium, ionized) | 18 | $205 | $11 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 13 | $184 | $14 |
| Automated urinalysis test | 38 | $115 | $3 |
| Blood count, hemoglobin | 32 | $102 | $3 |
| Blood glucose (sugar) test performed by hand-held instrument | 15 | $47 | $3 |
2016: 4 services
| New patient visit (45+ min) | 50 | $6,613 | $132 |
| Long return visit (40+ min) | 45 | $5,805 | $126 |
| Return visit (30+ min) | 13 | $1,225 | $94 |
| Short return visit (20+ min) | 13 | $899 | $64 |
2015: 7 services
| Emergency department visit with high level of medical decision making | 56 | $8,015 | $138 |
| New patient visit (45+ min) | 29 | $3,301 | $114 |
| Emergency department visit with moderate level of medical decision making | 33 | $2,610 | $77 |
| Emergency department visit with low level of medical decision making | 51 | $2,347 | $45 |
| Long return visit (40+ min) | 17 | $2,038 | $120 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 34 | $278 | $7 |
| X-ray of chest, 1 view, front | 17 | $135 | $8 |
2014: 7 services
| Emergency department visit with high level of medical decision making | 328 | $52,310 | $143 |
| Critical care, first 30-74 minutes | 59 | $11,359 | $189 |
| Emergency department visit with moderate level of medical decision making | 88 | $8,218 | $90 |
| Emergency department visit with low level of medical decision making | 126 | $5,810 | $45 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 306 | $2,470 | $7 |
| X-ray of chest, 1 view, front | 119 | $1,004 | $8 |
| X-ray of chest, 2 views, front and side | 11 | $105 | $10 |
2013: 7 services
| Emergency department visit with high level of medical decision making | 354 | $55,162 | $139 |
| Critical care, first 30-74 minutes | 93 | $18,011 | $186 |
| Emergency department visit with moderate level of medical decision making | 102 | $9,636 | $93 |
| Emergency department visit with low level of medical decision making | 118 | $6,000 | $49 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 298 | $2,382 | $7 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 13 | $1,176 | $90 |
| X-ray of chest, 1 view, front | 96 | $774 | $8 |
Medicaid work
$100,357 in 2024
Medicaid paid $100,357 for 780 billed services this clinician did in 2024, up to 41 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 311 | $77,196 |
| Return visit (30+ min) | 440 | $23,148 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; Influenza, A or B, each | 15 | $12 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | 14 | $0 |
| 2024 | 780 | 4 | 41 | $100,357 |
| 2023 | 1,190 | 7 | 43 | $113,576 |
| 2022 | 1,909 | 12 | 53 | $191,617 |
| 2021 | 2,823 | 14 | 92 | $259,191 |
| 2020 | 1,355 | 8 | 67 | $118,194 |
| 2019 | 985 | 4 | 88 | $132,795 |
| 2018 | 1,051 | 5 | 73 | $149,818 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 410 | $89,909 |
| Return visit (30+ min) | 647 | $17,407 |
| New patient visit (45+ min) | 17 | $3,154 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 41 | $2,052 |
| Infectious agent detection by nucleic acid (DNA or RNA); influenza virus, for multiple types or sub-types, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, first 2 types or sub-types | 12 | $1,054 |
| SARSCOV CORONAVIRUS AG IA | 35 | $0 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | 28 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 370 | $78,422 |
| Return visit (30+ min) | 939 | $59,851 |
| New patient visit (45+ min) | 195 | $36,723 |
| Infectious agent detection by nucleic acid (DNA or RNA); influenza virus, for multiple types or sub-types, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, first 2 types or sub-types | 79 | $7,377 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 149 | $7,286 |
| Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A, amplified probe technique | 44 | $1,474 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; respiratory syncytial virus | 22 | $275 |
| URINE PREGNANCY TEST | 12 | $103 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 27 | $59 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 15 | $47 |
| SARSCOV CORONAVIRUS AG IA | 26 | $0 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | 31 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 842 | $175,959 |
| Return visit (30+ min) | 1,036 | $41,235 |
| New patient visit (45+ min) | 212 | $31,719 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 119 | $5,747 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B | 35 | $2,188 |
| Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A, amplified probe technique | 65 | $2,176 |
| Short return visit (20+ min) | 119 | $85 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 25 | $52 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 161 | $18 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Streptococcus, group A | 32 | $7 |
| URINE PREGNANCY TEST | 34 | $6 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; Influenza, A or B, each | 14 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 525 | $103,710 |
| New patient visit (45+ min) | 27 | $4,661 |
| Return visit (30+ min) | 406 | $4,455 |
| Long return visit (40+ min) | 78 | $4,424 |
| Short return visit (20+ min) | 173 | $888 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 15 | $38 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 82 | $12 |
| URINE PREGNANCY TEST | 49 | $6 |
2019
| Clinic visit/encounter, all-inclusive | 504 | $95,004 |
| Return visit (30+ min) | 389 | $22,381 |
| Long return visit (40+ min) | 65 | $10,403 |
| New patient visit (45+ min) | 27 | $5,007 |
2018
| Clinic visit/encounter, all-inclusive | 651 | $120,339 |
| Return visit (30+ min) | 278 | $25,468 |
| New patient visit (45+ min) | 16 | $2,781 |
| Long return visit (40+ min) | 12 | $1,200 |
| MEASURE BLOOD OXYGEN LEVEL | 94 | $29 |
Drugs they prescribed that Part D paid
$1,663
Pharmacies billed $1,663 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 176) in 2024. At or below the middle of the specialty; the typical emergency medicine clinician is at 12%.
155 generic and fewer than 11 brand-name prescriptions · $1,663 in drug cost · 84 antibiotic prescriptions to 76 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Doxycycline Monohydrate | 22 | $217 | $10 |
| Cephalexin | 15 | $91 | $6 |
| Amoxicillin | 14 | $66 | $5 |
| Azithromycin | 11 | $53 | $5 |
| Prednisone | 13 | $30 | $2 |
Year by year
| 2024 | 176 | 126 | 0% (0) | None | $1,663 |
| 2023 | 193 | 142 | 0% (0) | None | $2,914 |
| 2022 | 193 | 148 | 0% (0) | None | $2,575 |
| 2021 | 265 | 192 | 0% (0) | None | $4,611 |
| 2020 | 179 | 138 | None | None | $8,182 |
| 2019 | 256 | 191 | None | None | $3,849 |
| 2018 | 263 | 187 | None | None | $5,280 |
| 2017 | 293 | 223 | 4% (11) | None | $4,359 |
| 2016 | 269 | 189 | 8% (22) | None | $4,663 |
| 2015 | 209 | 147 | 19% (40) | None | $3,942 |
| 2014 | 245 | 148 | 26% (64) | 8% | $3,671 |
| 2013 | 266 | 147 | 30% (80) | None | $3,675 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Albuterol Sulfate Hfa | 13 | $316 | $24 |
| Doxycycline Monohydrate | 27 | $270 | $10 |
| Azithromycin | 15 | $60 | $4 |
| Prednisone | 29 | $57 | $2 |
2022: 5 drugs
| Doxycycline Monohydrate | 17 | $247 | $15 |
| Cephalexin | 18 | $167 | $9 |
| Mupirocin | 13 | $78 | $6 |
| Cyclobenzaprine | 11 | $75 | $7 |
| Prednisone | 23 | $51 | $2 |
2021: 5 drugs
| Nitrofurantoin Mono-Macro | 20 | $284 | $14 |
| Doxycycline Monohydrate | 19 | $225 | $12 |
| Cephalexin | 19 | $169 | $9 |
| Ibuprofen | 17 | $66 | $4 |
| Prednisone | 27 | $55 | $2 |
2020: 5 drugs
| Nitrofurantoin Mono-Macro | 18 | $453 | $25 |
| Doxycycline Monohydrate | 11 | $185 | $17 |
| Cephalexin | 12 | $81 | $7 |
| Prednisone | 25 | $72 | $3 |
| Ibuprofen | 13 | $43 | $3 |
2019: 7 drugs
| Ventolin Hfa | 12 | $692 | $58 |
| Nitrofurantoin Mono-Macro | 20 | $359 | $18 |
| Doxycycline Monohydrate | 24 | $336 | $14 |
| Azithromycin | 28 | $227 | $8 |
| Doxycycline Hyclate | 12 | $184 | $15 |
| Prednisone | 41 | $120 | $3 |
| Ibuprofen | 13 | $42 | $3 |
2018: 6 drugs
| Ventolin Hfa | 15 | $827 | $55 |
| Nitrofurantoin Mono-Macro | 18 | $498 | $28 |
| Doxycycline Monohydrate | 20 | $206 | $10 |
| Azithromycin | 27 | $161 | $6 |
| Ibuprofen | 20 | $82 | $4 |
| Prednisone | 31 | $73 | $2 |
2017: 7 drugs
| Doxycycline Hyclate | 29 | $735 | $25 |
| Ventolin Hfa | 12 | $643 | $54 |
| Nitrofurantoin Mono-Macro | 20 | $577 | $29 |
| Doxycycline Monohydrate | 17 | $189 | $11 |
| Azithromycin | 27 | $182 | $7 |
| Prednisone | 33 | $104 | $3 |
| Amoxicillin | 11 | $62 | $6 |
2016: 8 drugs
| Nitrofurantoin Mono-Macro | 19 | $576 | $30 |
| Doxycycline Hyclate | 20 | $560 | $28 |
| Doxycycline Monohydrate | 21 | $272 | $13 |
| Azithromycin | 17 | $128 | $8 |
| Amoxicillin | 16 | $104 | $6 |
| Prednisone | 33 | $100 | $3 |
| Hydrocodone-Acetaminophen | 17 | $100 | $6 |
| Ibuprofen | 12 | $53 | $4 |
2015: 5 drugs
| Nitrofurantoin Mono-Macro | 12 | $391 | $33 |
| Hydrocodone-Acetaminophen | 39 | $163 | $4 |
| Azithromycin | 14 | $123 | $9 |
| Ibuprofen | 19 | $79 | $4 |
| Prednisone | 21 | $68 | $3 |
2014: 5 drugs
| Prochlorperazine Maleate | 14 | $848 | $61 |
| Nitrofurantoin Mono-Macro | 11 | $393 | $36 |
| Hydrocodone-Acetaminophen | 61 | $280 | $5 |
| Ibuprofen | 42 | $174 | $4 |
| Prednisone | 22 | $87 | $4 |
2013: 5 drugs
| Prochlorperazine Maleate | 18 | $875 | $49 |
| Hydrocodone-Acetaminophen | 72 | $452 | $6 |
| Ibuprofen | 55 | $221 | $4 |
| Famotidine | 11 | $76 | $7 |
| Prednisone | 11 | $35 | $3 |
Money from drug and device companies
$34 in 2022
| 2022 | 1 | 1 | None | $34 |
| 2020 | 1 | 1 | None | $14 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | Prevnar 20 | $34 | 1 payment
|
See the published payment
| Pfizer | Meals · 2022-09-06 | Prevnar 20 | $34 |
See earlier years (2020)
2020: $14
| Sun Pharmaceutical Industries | Kapspargo | $14 | 1 payment
|
Professional record
- NPI
- 1568485092
- Licence
- CA G50980California G50980: Current · expires 2027-07-31
- Trained
- University of California, Geffen School of Medicine, 1982
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207P00000X (207P00000X)
- Mailing address
- 577 Airport Blvd, Ste 300, Burlingame, CA, 94010
- NPI first listed
- 2006-07-25
- NPI last updated
- 2014-12-17
This is when the NPI record was last certified, not a medical board exam.